The Treatment of Iron-Deficiency Anemia with Intravenous Iron Dextran

Marchasin, Sidney; Wallerstein, Ralph O.

doi:10.1182/blood.v23.3.354.354

Cited by 65 publications

(20 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was not until 1964 that the first publication on the use of parenteral iron appeared. 6 Thirty-seven patients in a pediatric hospital received a total dose infusion of HMW-ID. All responded.…”

Section: Iron Dextranmentioning

confidence: 99%

The available intravenous iron formulations: History, efficacy, and toxicology

Auerbach

Macdougall

2017

Hemodialysis International

126

144

View full text Add to dashboard Cite

A number of intravenous iron formulations have been developed over the past 65 years which rely on dextran or other compounds to prevent uncontrolled release of free iron to the circulation. High molecular weight dextran was associated with a number of serious adverse reactions and was removed from markets worldwide in 2009. The preponderance of published evidence suggests that the formulations of parenteral iron currently available in the United States, including low molecular weight iron dextran, are all safe and effective and there are no major, clinically important differences among them in terms of either efficacy or safety. For patients with chemotherapy induced anemia or with anemia of end stage renal disease who are being treated with hemodialysis, it is reasonable to use any of the iron formulations, including iron sucrose and ferric gluconate, as frequent patient encounters with health caregivers are a routine part of care and the need to administer multiple low doses of IV iron is not a major disadvantage. However, a single infusion of a total iron dose is as effective and safe when giving iron preparations containing low molecular weight iron dextran, ferumoxytol, iron isomaltoside, or ferric carboxymaltose. Use of a single total dose infusion results in a decreased number of intravenous infusions with a lower cumulative risk for infusion reactions or extravasations, a reduced need for multiple office visits and repeated utilization of medical staff, and increased convenience for physicians and patients.

show abstract

Section: Iron Dextranmentioning

confidence: 99%

The available intravenous iron formulations: History, efficacy, and toxicology

Auerbach

Macdougall

2017

Hemodialysis International

126

144

View full text Add to dashboard Cite

show abstract

“…Experiences with the intravenous infusion of Imferon have been described lately (Basu, 1963;Gartlan, 1964;Lane, 1964;Powell, 1963) with a low incidence of generalized reactions of the type seen here, but with one fatality, according to the manufacturers, of an anaphylactoid nature. A varying degree of phlebitis has also been recorded, a complication reduced in frequency by Lane (1964) on decreasing the concentration of Imferon in the 5 per cent dextrose-water.…”

Section: Discussionmentioning

confidence: 68%

“…Additional Jectofer injections to replenish the stores to an equal degree would have taken another 6 days, a total time too long for in-patients. Basu (1963) Imferon, a method described by Wallerstein (1960) and Marchasin and Wallerstein (1964). These workers gave 2,000-3,000 mg. iron in single doses to 6 patients, and 250-1,000 mg. to 31 others, noting only one generalized and one local reaction.…”

Section: Discussionmentioning

confidence: 99%

Parenteral Iron Therapy in Pregnancy

Dawson¹,

Goldthorp²,

Spencer³

1965

BJOG

View full text Add to dashboard Cite

AND PARENTERAL iron therapy is of particular value in pregnancy, and two preparations are in common use today. In this paper we describe trials which were undertaken to determine the more suitable one for use in a hospital of our kind, which with a shortage of antenatal beds caters for a population containing a high proportion of social classes IV and V. More than 600 patients were treated for anaemia last year in the antenatal wards.

show abstract

“…Intravenously administered iron dextran has gained widespread acceptance as a safe and reliable method of correcting iron deficiency anaemia and replenishing body iron stores (Marchasin & Wallerstein, 1964;Bonnar, 1965 ;Will & Groden, 1968). Henderson & H i h i a n (1969) reported that the availability of a portion of these iron stores for erythropoiesis was reduced.…”

mentioning

confidence: 99%

Utilization of Iron Dextran in Recurrent Iron Deficiency Anaemia

1975

View full text Add to dashboard Cite

Previously published studies have documented a reduction in the rate at which iron stores laid down by iron dextran therapy can be utilized for haemoglobin synthesis after the acute demands of haemorrhage and phlebotomy. In order to determine if a defect in the mobilization of these stores exists in the face of a chronic stimulus to red cell production, 93 patients who had previously received a total dose infusion of iron dextran were examined for a recurrence of iron deficiency anaemia, and in those in whom anaemia had recurred, iron stores were assessed by marrow aspiration. Twenty of the 93 patients were found to have recurrent iron deficiency anaemia, and marrow aspiration in all failed to demonstrate stainable iron stores. Although the rate at which iron dextran can be mobilized from storage sites is reduced, the present study demonstrates that ultimately these stores are fully utilizable.

show abstract

The Treatment of Iron-Deficiency Anemia with Intravenous Iron Dextran

Cited by 65 publications

References 5 publications

The available intravenous iron formulations: History, efficacy, and toxicology

The available intravenous iron formulations: History, efficacy, and toxicology

Parenteral Iron Therapy in Pregnancy

Utilization of Iron Dextran in Recurrent Iron Deficiency Anaemia

Contact Info

Product

Resources

About